LAUNCHING SOON: Global Healthcare Leaders ETF (HLTH)
  • Blog

    LAUNCHING SOON: Global Healthcare Leaders ETF (HLTH)

    Arian Neiron, Managing Director
    19 August 2020

    Global Healthcare is a growth sector
    The formula driving global health care expenditures higher in the long run is:


    In an Australian first, investors will soon be able to invest in an ETF of healthcare companies from around the world selected for their financial fundamentals focused on ‘growth at a reasonable price’ (GARP). We believe it is these companies that are best positioned to benefit from the growth in global healthcare.

    The VanEck Vectors Global Healthcare Leaders ETF (HLTH) will be the only smart beta global healthcare ETF on ASX.

    Healthcare is one of the sectors best positioned to harness the major global growth trends we see ahead.

    The HLTH opportunity
    Global growth opportunity
    A sector with significant growth potential due to shifting global demographics, social changes, research & development and innovation supporting increased demand in healthcare-related products and services.

    A portfolio of global healthcare leaders comprising the most fundamentally strong companies
    Invests in 50 fundamentally sound and attractively valued companies with the best growth prospects in the healthcare sector.

    Targeted exposure and diversification
    A portfolio which targets focused exposure to healthcare and offers true diversification by equally weighting across companies.


    Important Notice: This information is issued by VanEck Investments Limited ABN 22 146 596 116 AFSL 416755 (‘VanEck’) as the responsible entity and issuer of VanEck Vectors Global Healthcare Leaders ETF (the Fund). Units in the Fund are not currently available. The Fund has been registered by ASIC and VanEck has lodged an application with ASX for units in the Fund to be admitted to trading status on ASX under the code ‘HLTH’.

    This information is general in nature and not financial advice. It does not take into account any person’s individual objectives, financial situation or needs. Before making an investment decision investors should read the product disclosure statement and with the assistance of a financial adviser consider if it is appropriate for their circumstances. The PDS has been lodged with ASIC. A copy is currently available from our offices and will be available after the end of the exposure period at or by calling 1300 68 38 37.

    HLTH invests in international markets which have specific and heightened risks that are in addition to the typical risks associated with investing in the Australian equities market. These include ASX trading time differences, foreign currency, country or sector concentration, and political, regulatory and tax risks. The PDS details the key risks.
    No member of the VanEck group guarantees the repayment of capital, the payment of income, performance, or any particular rate of return from HLTH.